<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146296">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906086</url>
  </required_header>
  <id_info>
    <org_study_id>legume consumption in adults</org_study_id>
    <nct_id>NCT01906086</nct_id>
  </id_info>
  <brief_title>Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults</brief_title>
  <official_title>Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among First Degree Relatives of Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The  aim of this randomized cross-over study was to determine the effects of legume
      consumption on adiponectin and inflammatory factors among first degree relatives of diabetic
      patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>high sensitive C reactive protein (mg/l)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>amounts of hs-CRP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (pg/ml)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>amounts of IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor-α (pg/ml)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>amounts of TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin (ng/ml)</measure>
    <time_frame>14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>amounts of adiponectin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>legume consumption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>legume consumption, 4 servings per week, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy dietary recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no nutritional intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional intervention</intervention_name>
    <arm_group_label>legume consumption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>life style intervention</intervention_name>
    <arm_group_label>healthy dietary recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 30 years

          -  no history of chronic diseases

          -  no use of blood glucose lowering drugs

        Exclusion Criteria:

          -  do not use recommended amounts of legumes

          -  incidence of chronic diseases during the study

          -  to start use of blood glucose lowering drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Isfahan University of Medical Sciences</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Leila Azadbakht</investigator_full_name>
    <investigator_title>Isfahan University of Medical Sciences</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
